Cancers, Vol. 12, Pages 2389: Chemotherapy and Survival in Patients with Primary High-Grade Extremity and Trunk Soft Tissue Sarcoma

Cancers, Vol. 12, Pages 2389: Chemotherapy and Survival in Patients with Primary High-Grade Extremity and Trunk Soft Tissue Sarcoma Cancers doi: 10.3390/cancers12092389 Authors: Danielle S. Graham Ritchell van Dams Nicholas J. Jackson Mykola Onyshchenko Mark A. Eckardt Benjamin J. DiPardo Scott D. Nelson Bartosz Chmielowski Jacob E. Shabason Arun S. Singh Fritz C. Eilber Anusha Kalbasi The use of upfront chemotherapy for primary localized soft tissue sarcoma (STS) of the extremity and trunk is debated. It remains unclear if chemotherapy adds clinical benefit, which patients are likely to benefit, and whether the timing of therapy affects outcomes. We used the National Cancer Database (NCDB) to examine the association between overall survival (OS) and chemotherapy in 5436 patients with the five most common subtypes of STS with primary disease localized to the extremity or trunk, mirroring the patient population of a modern phase 3 clinical trial of neoadjuvant chemotherapy. We then examined associations between timing of multi-agent chemotherapy (neoadjuvant or adjuvant) and OS. We used a Cox proportional hazards model and propensity score matching (PSM) to account for covariates including demographic, patient, clinical, treatment, and facility factors. In the overall cohort, we observed no association between multi-agent chemotherapy or its timing and improved OS. Multi-agent chemotherapy was associated with improved OS in several subgroups, incl...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research